Freeline Therapeutics Holdings plc - FRLN
About Gravity Analytica
Recent News
- 06.06.2025 - Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting
- 05.27.2025 - Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease
- 05.15.2025 - Spur Therapeutics Presents Positive New Clinical and Preclinical Data on Its Gene Therapy Programs at ASGCT 28th Annual Meeting
- 05.01.2025 - Spur Therapeutics to Participate in Citizens JMP 2025 Life Sciences Conference
- 04.28.2025 - Spur Therapeutics Announces Oral and Poster Presentations Highlighting Data from Clinical and Preclinical Programs at Upcoming ASGCT Annual Meeting
- 02.04.2025 - Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium™
- 02.03.2025 - Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
- 02.03.2025 - Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
- 01.23.2025 - Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium
- 12.03.2024 - Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program